MARKER LESION STUDY OF ORAL ERDAFITINIB IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2: UPDATED COHORT 3 RESULTS

EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL

UPDATED EFFICACY AND SAFETY OF ORAL ERDAFITINIB IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE, HIGH-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2 COHORT 2

Late Breaking Abstract: First results from BOND-003, a Phase 3 study of intravesical Cretostimogene grenadenorepvec monotherapy for patients with high-risk BCG- unresponsive Non-Muscle Invasive Bladder Cancer

TREATMENT OF LOW-GRADE INTERMEDIATE-RISK NONMUSCLE-INVASIVE BLADDER CANCER WITH UGN-102 ± TRANSURETHRAL RESECTION OF BLADDER TUMOR (TURBT) COMPARED TO TURBT MONOTHERAPY: THE PHASE 3 ATLAS TRIAL

Late Breaking Abstract: PRIMARY CHEMOABLATION FOR RECURRENT LOW GRADE INTERMEDIATE RISK (LG IR) NMIBC: THE ENVISION TRIAL

CHARACTERISTICS, TREATMENTS, AND OUTCOMES OF PATIENTS WITH A FAMILY HISTORY OF PROSTATE CANCER AFTER PROGRESSION TO MCRPC: A POST HOC ANALYSIS OF THE TRUMPET REGISTRY

ADVANCED-1: PHASE 1A DOSE-FINDING, OPEN-LABEL STUDY TO EVALUATE SAFETY AND TOXICITY OF INTRAVESICAL INSTILLATION OF TARA-002 IN ADULTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER

Active Surveillance versus Primary Intervention for Clinical T1a Kidney Tumors: Contemporary results after Fourteen-Year Experience of the DISSRM Prospective Comparative Study

CONNEXIN-26 EXPRESSION IS ASSOCIATED WITH DISEASE OUTCOMES IN CLEAR CELL RENAL CELL CARCINOMA AND MAY BE A SOURCE OF INTRATUMORAL ADENOSINE

ADJUVANT PEMBROLIZUMAB FOR RENAL CELL CARCINOMA (KEYNOTE-564): EXPLORATORY ANALYSIS ACROSS UCLA INTEGRATED STAGING SYSTEM RISK GROUPS AND DISEASE STAGE

SUBCUTANEOUS FAT AREA AS A RISK FACTOR FOR PARASTOMAL HERNIA FOLLOWING CYSTECTOMY AND ILEAL CONDUIT: DATA FROM THE PUBMIC TRIAL

LEGEND, A PHASE 1/2 STUDY OF DETALIMOGENE VORAPLASMID (EG-70) INTRAVESICAL MONOTHERAPY DEMONSTRATED CLINICAL RESPONSES IN BCG-UNRESPONSIVE NMIBC PATIENTS WITH CIS

PHASE 1B/2 DOSE-EXPANSION, OPEN-LABEL STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF INTRAVESICAL INSTILLATION OF TARA-002 IN ADULTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER